MX2019000188A - Composiciones y metodos basados en crispr/cas9 para el tratamiento del cancer. - Google Patents
Composiciones y metodos basados en crispr/cas9 para el tratamiento del cancer.Info
- Publication number
- MX2019000188A MX2019000188A MX2019000188A MX2019000188A MX2019000188A MX 2019000188 A MX2019000188 A MX 2019000188A MX 2019000188 A MX2019000188 A MX 2019000188A MX 2019000188 A MX2019000188 A MX 2019000188A MX 2019000188 A MX2019000188 A MX 2019000188A
- Authority
- MX
- Mexico
- Prior art keywords
- crispr
- methods
- cas9
- treating cancer
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
En este documento se describen métodos para prevenir, inhibir, o tratar el cáncer en un sujeto. En el presente documento también se proporcionan métodos para alterar la expresión de uno o más productos génicos en una célula, como una célula cancerosa. Dichos métodos pueden comprender utilizar un sistema de nucleasa modificada, como las Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Interespaciadas (CRISPR)/CRISPR asociadas (Cas) 9 (CRISPR-Cas9) que comprenden un promotor H1 bidireccional y los ARNg dirigidos a oncogenes (rAAV-Onco-CRISPR) o genes supresores de tumores (rAAV-TSG) empaquetados en una partícula compacta de virus adeno-asociado (AAV). Dichos métodos pueden comprender la co-administración o proporcionar concurrentemente un adenovirus empaquetador de virus adeno-asociado recombinante (Ad-rAAVpack) con el sistema de nucleasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662358339P | 2016-07-05 | 2016-07-05 | |
PCT/US2017/040696 WO2018009525A1 (en) | 2016-07-05 | 2017-07-05 | Crispr/cas9-based compositions and methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000188A true MX2019000188A (es) | 2019-06-20 |
Family
ID=60913122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000188A MX2019000188A (es) | 2016-07-05 | 2017-07-05 | Composiciones y metodos basados en crispr/cas9 para el tratamiento del cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200069818A1 (es) |
EP (1) | EP3481431A4 (es) |
JP (1) | JP2019520394A (es) |
KR (1) | KR20190039115A (es) |
CN (1) | CN109963598A (es) |
AU (1) | AU2017292772A1 (es) |
BR (1) | BR112019000107A2 (es) |
CA (1) | CA3029908A1 (es) |
CL (1) | CL2019000023A1 (es) |
EA (1) | EA201990214A1 (es) |
IL (1) | IL264034A (es) |
MX (1) | MX2019000188A (es) |
SG (1) | SG11201900028VA (es) |
WO (1) | WO2018009525A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA039693B1 (ru) | 2014-06-16 | 2022-02-28 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для экспрессии рнк-проводников crispr с использованием промотора h1 |
US9855445B2 (en) | 2016-04-01 | 2018-01-02 | Varian Medical Systems, Inc. | Radiation therapy systems and methods for delivering doses to a target volume |
US10183179B1 (en) | 2017-07-21 | 2019-01-22 | Varian Medical Systems, Inc. | Triggered treatment systems and methods |
US10843011B2 (en) | 2017-07-21 | 2020-11-24 | Varian Medical Systems, Inc. | Particle beam gun control systems and methods |
US11712579B2 (en) | 2017-07-21 | 2023-08-01 | Varian Medical Systems, Inc. | Range compensators for radiation therapy |
US10549117B2 (en) | 2017-07-21 | 2020-02-04 | Varian Medical Systems, Inc | Geometric aspects of radiation therapy planning and treatment |
US11590364B2 (en) | 2017-07-21 | 2023-02-28 | Varian Medical Systems International Ag | Material inserts for radiation therapy |
US10092774B1 (en) | 2017-07-21 | 2018-10-09 | Varian Medical Systems International, AG | Dose aspects of radiation therapy planning and treatment |
EP3967367A1 (en) | 2017-11-16 | 2022-03-16 | Varian Medical Systems Inc | Increased beam output and dynamic field shaping for radiotherapy system |
CN108265116A (zh) * | 2018-01-22 | 2018-07-10 | 上海市第人民医院 | Klf4作为肝癌疾病诊断和治疗靶点 |
AU2019226527A1 (en) * | 2018-03-02 | 2020-10-01 | Generation Bio Co. | Closed-ended DNA (ceDNA) vectors for insertion of transgenes at genomic safe harbors (GSH) in humans and murine genomes |
AU2019234926A1 (en) * | 2018-03-15 | 2020-10-08 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
CN112533627A (zh) * | 2018-03-27 | 2021-03-19 | G+Flas 生命科学公司 | 序列特异性体内细胞靶向 |
TW202126325A (zh) * | 2018-03-27 | 2021-07-16 | 南韓商G+Flas生命科學有限公司 | 用於治療癌症之包含引導rna及內切酶的藥學組成物 |
EP3781131A4 (en) * | 2018-04-19 | 2022-06-01 | Board of Regents, The University of Texas System | THERAPEUTIC MODULATION OF TUMOR SUPPRESSORS USING EXOSOMES |
CN108588194A (zh) * | 2018-05-28 | 2018-09-28 | 北京诺禾致源科技股份有限公司 | 利用高通量测序数据检测肿瘤突变负荷的方法及装置 |
US20210324478A1 (en) * | 2018-07-18 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators |
WO2020022802A1 (ko) * | 2018-07-25 | 2020-01-30 | 주식회사 툴젠 | 인위적인 유전자 조작을 통한 자가면역질환 치료 |
US10910188B2 (en) | 2018-07-25 | 2021-02-02 | Varian Medical Systems, Inc. | Radiation anode target systems and methods |
EP3851528A4 (en) * | 2018-09-12 | 2023-12-06 | Institute for Basic Science | COMPOSITION FOR INDUCATING DEATH OF CELLS HAVING MUTATED GENE AND METHOD FOR INDUCATING DEATH OF CELLS HAVING MODIFIED GENE USING THE COMPOSITION |
IT201800009431A1 (it) * | 2018-10-15 | 2020-04-15 | Universita' Degli Studi Di Siena | Sistema CRISPR-Cas per l’editing genomico. |
EP3640329A1 (en) * | 2018-10-18 | 2020-04-22 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Gene editing based cancer treatment |
US10814144B2 (en) | 2019-03-06 | 2020-10-27 | Varian Medical Systems, Inc. | Radiation treatment based on dose rate |
US11116995B2 (en) | 2019-03-06 | 2021-09-14 | Varian Medical Systems, Inc. | Radiation treatment planning based on dose rate |
US11090508B2 (en) | 2019-03-08 | 2021-08-17 | Varian Medical Systems Particle Therapy Gmbh & Co. Kg | System and method for biological treatment planning and decision support |
US11103727B2 (en) | 2019-03-08 | 2021-08-31 | Varian Medical Systems International Ag | Model based PBS optimization for flash therapy treatment planning and oncology information system |
CN109897854B (zh) * | 2019-03-28 | 2020-12-25 | 江苏浦珠生物医药科技有限公司 | 一种双sgRNA位点敲除ZYG11A基因的CRISPR/Cas9***与应用 |
WO2020237208A1 (en) | 2019-05-23 | 2020-11-26 | Christiana Care Health Services, Inc. | Gene knockout of variant nrf2 for treatment of cancer |
US10918886B2 (en) | 2019-06-10 | 2021-02-16 | Varian Medical Systems, Inc. | Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping |
WO2021050937A1 (en) * | 2019-09-12 | 2021-03-18 | The Wistar Institute Of Anatomy And Biology | Methods for the treatment of arid1a-deficient cancers |
US11291859B2 (en) | 2019-10-03 | 2022-04-05 | Varian Medical Systems, Inc. | Radiation treatment planning for delivering high dose rates to spots in a target |
CN110772646A (zh) * | 2019-10-15 | 2020-02-11 | 天津大学 | 共载多烯紫杉醇与crispr/cas9脂质体及应用 |
KR102337860B1 (ko) * | 2019-11-05 | 2021-12-10 | 중앙대학교 산학협력단 | 슈와크만-보디안-다이아몬드 증후군 유전자의 발현 억제제를 유효성분으로 포함하는 유방암 치료제 효율 증진용 조성물 |
WO2021182917A1 (ko) * | 2020-03-12 | 2021-09-16 | 기초과학연구원 | 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법 |
US11865361B2 (en) | 2020-04-03 | 2024-01-09 | Varian Medical Systems, Inc. | System and method for scanning pattern optimization for flash therapy treatment planning |
US20230257771A1 (en) * | 2020-04-20 | 2023-08-17 | Christiana Care Health Services, Inc. | Aav delivery system for lung cancer treatment |
AU2021261423A1 (en) * | 2020-04-24 | 2022-12-08 | Aadigen, Llc | Compositions for treating cancer with KRAS mutations and uses thereof |
US11541252B2 (en) | 2020-06-23 | 2023-01-03 | Varian Medical Systems, Inc. | Defining dose rate for pencil beam scanning |
US11957934B2 (en) | 2020-07-01 | 2024-04-16 | Siemens Healthineers International Ag | Methods and systems using modeling of crystalline materials for spot placement for radiation therapy |
WO2023070108A1 (en) * | 2021-10-22 | 2023-04-27 | Spotlight Therapeutics | Guide rnas and uses thereof |
WO2023143474A1 (en) * | 2022-01-26 | 2023-08-03 | Anchordx Medical Co., Ltd. | Methods for treating gastric cancer |
WO2023205844A1 (en) * | 2022-04-26 | 2023-11-02 | Peter Maccallum Cancer Institute | Nucleic acids and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116064532A (zh) * | 2012-10-23 | 2023-05-05 | 基因工具股份有限公司 | 用于切割靶dna的组合物及其用途 |
RU2716421C2 (ru) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов |
US20150098954A1 (en) * | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
EA039693B1 (ru) * | 2014-06-16 | 2022-02-28 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для экспрессии рнк-проводников crispr с использованием промотора h1 |
WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
KR20230098910A (ko) * | 2014-10-31 | 2023-07-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
-
2017
- 2017-07-05 SG SG11201900028VA patent/SG11201900028VA/en unknown
- 2017-07-05 MX MX2019000188A patent/MX2019000188A/es unknown
- 2017-07-05 WO PCT/US2017/040696 patent/WO2018009525A1/en unknown
- 2017-07-05 KR KR1020197003437A patent/KR20190039115A/ko unknown
- 2017-07-05 JP JP2019500338A patent/JP2019520394A/ja active Pending
- 2017-07-05 BR BR112019000107-7A patent/BR112019000107A2/pt not_active Application Discontinuation
- 2017-07-05 EP EP17824792.0A patent/EP3481431A4/en not_active Withdrawn
- 2017-07-05 US US16/315,468 patent/US20200069818A1/en not_active Abandoned
- 2017-07-05 EA EA201990214A patent/EA201990214A1/ru unknown
- 2017-07-05 CA CA3029908A patent/CA3029908A1/en not_active Abandoned
- 2017-07-05 AU AU2017292772A patent/AU2017292772A1/en not_active Abandoned
- 2017-07-05 CN CN201780054063.7A patent/CN109963598A/zh active Pending
-
2018
- 2018-12-31 IL IL264034A patent/IL264034A/en unknown
-
2019
- 2019-01-04 CL CL2019000023A patent/CL2019000023A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2019000023A1 (es) | 2019-06-21 |
EP3481431A4 (en) | 2020-01-01 |
KR20190039115A (ko) | 2019-04-10 |
US20200069818A1 (en) | 2020-03-05 |
IL264034A (en) | 2019-01-31 |
EP3481431A1 (en) | 2019-05-15 |
JP2019520394A (ja) | 2019-07-18 |
EA201990214A1 (ru) | 2019-11-29 |
AU2017292772A1 (en) | 2019-02-21 |
WO2018009525A1 (en) | 2018-01-11 |
WO2018009525A8 (en) | 2019-02-07 |
SG11201900028VA (en) | 2019-01-30 |
CA3029908A1 (en) | 2018-01-11 |
BR112019000107A2 (pt) | 2019-04-09 |
CN109963598A (zh) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000188A (es) | Composiciones y metodos basados en crispr/cas9 para el tratamiento del cancer. | |
MX2019000262A (es) | Composiciones basadas en crispr/cas9 y metodos para el tratamiento de degeneraciones retinianas. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
GB2557123A (en) | Modified cells and methods of therapy | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
MX2021005314A (es) | Compuestos biciclicos. | |
WO2016109546A3 (en) | Methods and compositions for prognosis and treatment of cancers | |
MX2017012407A (es) | Celulas t modificadas y métodos para hacer y usar las mismas. | |
WO2016137235A3 (ko) | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 | |
WO2017176628A8 (en) | Methods for solid tumor treatment | |
NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
MX2017009724A (es) | Terapias de combinacion para tratar canceres. | |
MY185579A (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2023011105A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
MA39818A (fr) | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques | |
MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
WO2018064588A3 (en) | Tert immunogenic compositions and methods of treatment using the same | |
WO2017042634A3 (en) | Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
MX2021005980A (es) | Adenovirus y metodos para usar adenovirus. | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy |